阿仑磷酸钠片联合唑来膦酸注射液治疗骨质疏松症患者的药物经济学评价

目的探讨阿仑磷酸钠片联合唑来膦酸注射液治疗骨质疏松症的成本-效果。方法选取2016年12月至2018年2月于阜新市中医医院骨伤科治疗的138例骨质疏松症患者作为研究对象,按照随机数字表法分为对照组和观察组,每组69例。对照组给予阿仑磷酸钠片治疗,观察组在对照组治疗基础上采用唑来膦酸注射液治疗,比较两组患者治疗效果,并进行成本-效果分析。结果观察组治疗有效率为97.10%,显著高于对照组的75.36%,差异有统计学意义(P<0.05)。治疗后,与对照组比较,观察组患者腰椎骨、股骨颈和Ward’s三角区骨密度水平显著提高(P<0.05),血清Ca2+、骨特异性碱性磷酸酶(ALP)、降钙素(HCT)水平显著提高(P<0.05),成本-效果比提高(P<0.05),不良反应发生率降低(P<0.05)。结论阿仑磷酸钠片联合唑来膦酸注射液治疗可明显提高骨质疏松症患者疗效,调节骨密度,有助于骨代谢指标恢复,但其成本也较高。     

The association between osteoporosis and patient outcomes in Japan

Objective To quantify the burden of osteoporosis and examine the interplay between osteoporosis and various comorbidities as it relates to patient outcomes.

Methods Data from the 2011 Japan National Health and Wellness Survey (NHWS; n?=?30 000), an internet health survey fielded to a nationally representative sample of the Japanese population were used. Only women between the ages of 50–90 years were included in the analyses (n?=?6950).

Results Compared with matched controls (n?=?404), patients with osteoporosis (n?=?404) had lower MCS scores (48.94 vs 51.63), PCS scores (45.57 vs 49.12) (all p?<?0.05). The presence of osteoporosis was associated with worse patient outcomes among those with hypertension, high cholesterol, and insomnia, among other conditions.

Conclusions The results suggest a significant quality-of-life and economic burden for patients with osteoporosis in Japan. Moreover, in a complex co-morbid environment, the presence of osteoporosis contributes more to patient outcomes than other chronic conditions.     

骨化三醇的临床应用与不良反应

本文在阐述了骨化三醇的临床应用现状的基础上，介绍了目前临床应用广泛的病症的治疗机理、特点，并就新应用、新不良反应进行了介绍，对骨化三醇的临床应用具有参考价值。